Biotech Firm Amyris Hit with $881M Suit over Cannabinoid IP

By Willis Jacobson
Sep 17, 2020
A cannabinoid manufacturer has sued biotech company Amyris for $881M, amid a fraught 18-months relationship between the companies. Among other allegations, the lawsuit claims Amyris used the partnership to artificially inflate its own value and then leveraged the plaintiff’s trade...

This content is FREE for registered users.

To view this content you need to register as a Weedweek member.

If you are already a member please login below.